Literature DB >> 9448886

Oral cyclophosphamide for refractory or relapsing thrombotic thrombocytopenic purpura (TTP)

M S Hertzberg, J Koutts.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9448886     DOI： 10.1111/j.1445-5994.1997.tb02204.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN： 0004-8291


× No keyword cloud information.
  5 in total

Review 1.  How I treat refractory thrombotic thrombocytopenic purpura.

Authors:  Farzana A Sayani; Charles S Abrams
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

Review 2.  Sjögren's syndrome initially presented as thrombotic thrombocytopenic purpura in a male patient: a case report and literature review.

Authors:  Xiaohan Xu; Tienan Zhu; Di Wu; Lu Zhang
Journal:  Clin Rheumatol       Date:  2017-11-13       Impact factor: 2.980

Review 3.  Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis.

Authors:  Nay M Tun; Gina M Villani
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

4.  Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab.

Authors:  Mouhamed Yazan Abou-Ismail; Yasmin Arafah; Pingfu Fu; Shufen Cao; Alvin H Schmaier; Lalitha Nayak
Journal:  Front Med (Lausanne)       Date:  2020-10-28

Review 5.  Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Ashley Hanlon; Ara Metjian
Journal:  Ther Adv Hematol       Date:  2020-02-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.